The Role of HDAC Inhibition in the Frontline Setting
To continue, select another chapter from the Chapter List
Expected time to complete this activity as designed: 15 minutes
There are no fees for participating in or receiving credit for this online activity.
In this activity, Dr. Atallah explains the mechanism of action and emerging role of HDAC inhibitors in the treatment of acute myeloid leukemia. In his interview, Dr. Atallah answers questions regarding emerging data and efficacy reported in clinical trials to date, looking at response as a single agent as well as studies evaluating combination therapies with HDAC inhibitors.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with acute myeloid leukemia.
Upon completion of this educational activity, participants should be able to:
- Identify the therapeutic rationale for combining HDAC inhibitors with other agents for patients with newly diagnosed AML, including hypomethylating agents
- Describe promising clinical trials of regimens that include HDAC inhibitors for the treatment of patients with newly diagnosed AML
The Role of HDAC Inhibition in the Frontline Setting – Ehab Atallah, MD
Instructions for Participation and Credit
This activity is eligible for credit through April 22, 2021. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Ehab Atallah, MD
Professor of Medicine
Section Head, Hematologic Malignancies/BMT
Division of Hematology & Oncology
Medical College of Wisconsin
Dr. Ehab Atallah received his medical degree from Cairo University School of Medicine. He completed an internal medicine residency in the Cleveland Clinic Health System, a fellowship in hematology/oncology at the Karmanos Cancer Center, where he served as chief fellow, as well as a leukemia fellowship at MD Anderson Cancer Center. Dr. Atallah is Professor of Medicine at the Medical College of Wisconsin, Division of Hematology and Oncology, specializing in leukemia and myelodysplastic syndromes at Froedtert Hospital.
Dr. Atallah is board certified in internal medicine, medical oncology, and hematology. He has authored numerous publications, including journal articles and meeting abstracts. His current research interests include the treatment of patients with chronic myelogenous leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, acute myelogenous leukemia, myeloproliferative neoplasms, and myelodysplastic syndromes.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Helsinn.
©2020 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.25 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-20-015-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Ehab Atallah has received honoraria related to speakers’ bureau activities from Jazz Pharmaceuticals plc and as a consultant from AbbVie Inc., Novartis AG, and Takeda Oncology. He has received grant support related to research activities from Takeda Oncology.
Andrew Bowser, contributing author, has disclosed no relevant financial relationships.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Andrea Mathis, Project Manager, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
- Chapter 1: Pretest
- Chapter 2: The Role of HDAC Inhibition in the Frontline Setting
- Assessment and Evaluation